1. Homepage
  2. Equities
  3. Israel
  4. TEL AVIV STOCK EXCHANGE
  5. Panaxia Labs Israel Ltd
  6. News
  7. Summary
    PNAX   IL0011043630

PANAXIA LABS ISRAEL LTD

(PNAX)
  Report
End-of-day quote TEL AVIV STOCK EXCHANGE  -  05-21
0.5990 ILS   -3.85%
03/31Panaxia Labs Israel Ltd Reports Earnings Results for the Full Year Ended December 31, 2021
CI
2021Panaxia Labs Israel Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
CI
2021Panaxia Labs Israel Ltd Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Panaxia Labs Israel Ltd announced that it has received ILS 17 million in funding

11/08/2020 EDT

Panaxia Labs Israel Ltd (TASE:PNAX) announced a private placement of 6,800,000 common shares at a price of ILS 2.50 for gross proceeds of ILS 17,000,000 on November 8, 2020. The company will also issue 6,800,000 warrants, each exercisable into 1 common share at an exercise price of ILS 3.28 per warrant for a period of 3 years in the transaction. The shares were issued without par value representing 5.69% of the issued and paid up share capital of the company in the transaction and subject to a six month hold period. The transaction has been approved by the board of directors of the company.


© S&P Capital IQ 2020
All news about PANAXIA LABS ISRAEL LTD
03/31Panaxia Labs Israel Ltd Reports Earnings Results for the Full Year Ended December 31, 2..
CI
2021Panaxia Labs Israel Ltd Reports Earnings Results for the Third Quarter and Nine Months ..
CI
2021Panaxia Labs Israel Ltd Reports Earnings Results for the Second Quarter Ended June 30, ..
CI
2021Panaxia Labs Israel Ltd. and Neuraxpharm Expands Strategic Collaboration to Poland
CI
2021IM Cannabis Corp.
AQ
2021IMC Holdings Ltd. agreed to acquire Israel's Largest Retail and Online Pharmacy Busines..
CI
2021Panaxia Labs Israel Ltd Provides Revenue Guidance for the First Quarter of 2021
CI
2021Panaxia Labs Israel Ltd Reports Earnings Results for the Fourth Quarter and Year 2020
CI
2021Government of Cyprus Selects Panaxia Labs Israel Ltd. to Supply Premium Oils
CI
2021Neuraxpharm France and Panaxia Labs Select the Participation in A Pilot Program for the..
CI
More news
Financials
Sales
Net income
Net Debt
P/E ratio
Yield
Capitalization 88,3 M 26,5 M 26,5 M
EV / Sales -1
EV / Sales 0
Nbr of Employees -
Free-Float 33,5%
Chart PANAXIA LABS ISRAEL LTD
Duration : Period :
Panaxia Labs Israel Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Dadi Segal Chief Executive Officer & Director
Jonathan B. Kolber Chairman
Eran Goldberg Chief Technology Officer
Tamar Hinenzon Meiri Vice President-Operations
Tal Yaron Eldar Independent External Director
Sector and Competitors
1st jan.Capi. (M$)
PANAXIA LABS ISRAEL LTD-36.48%27
CINTAS CORPORATION-17.95%37 207
TELEPERFORMANCE SE-21.96%18 955
BUREAU VERITAS SA-9.36%12 629
EDENRED SE11.51%11 862
LG CORP.-6.80%10 454